Cell Line Development Services - Abzena

Cell Line Development

Rapidly progress therapeutic protein & recombinant vaccine programs from DNA to RCB in 10 weeks with AbZelectPRO™, our enhanced cell line development solution.

Discover AbZelectPRO™ Download Info Sheet

We are moving cell line development forward

Go from DNA to RCB in just 10 Weeks with AbZelectPRO™

Go from DNA to RCB in just 10 Weeks with AbZelectPRO™

CLD Services - Reducing cell line development timelines by 30%

Reducing CLD development timelines by >30%

CLD Services - Rapid delivery of high-producing cell lines up to 8g/L

Rapid delivery of high-producing, stable cell lines up to 8g/L

Discover AbZelectPRO™

At Abzena we understand the importance of optimal cell line development (CLD). With over 20 years of expertise and a commitment to quality excellence, we can reduce your CLD timelines by >30%. Our fully integrated AbZelectPRO™ platform accelerates timelines and de-risks CLD programs with quick doubling times. It efficiently enables the rapid delivery of high-producing cell lines up to 8g/L for complex biologics or bioconjugates.

Generation of early-stage product from fast stable cell line pools enables us to confirm the Quality Target Product Profile (QTPP). In parallel, this material can be used to initiate formulation development and analytical method development, taking these key activities off the critical path. Material from stable cell line pools can also help accelerate process development for antibody-drug conjugates.

We have developed multiple cell lines that have progressed from process development into manufacture and through clinical trials. With years of experience in providing cell line development services, our team has successfully expressed biologics including antibodies, antibody fragments, bispecific antibodies, fusion proteins, growth factors and vaccines.

Contact Us

Our Integrated Approach to Cell Line Development

AbZelectPRO™: Enhanced Cell Line Development - Abzena

We offer an integrated cell line development process, shortening timelines to IND enabling material. This is supported by using fast stable pools to generate early-stage material for characterization, pre-formulation, analytics and lead molecule selection. We offer:

  • Fast development of high-quality clones for manufacture
  • Platform processes for rapid progression through process development
  • Use of widely available commercial media and feeds for easier transfer
  • Strong analytics and bioassay capabilities to ensure product quality as well as productivity
  • Global project management to ensure the smooth progression of projects for on-time delivery
Contact Us

AbZelectPRO™ Info Sheet

AbZelect™ & AbZelectPRO™: Enhanced Cell Line Development - Abzena

For more complex biologic programs, we can deliver increased productivity by enhancing our AbZelectPRO™ platform. This combines our existing CHO cell line with ProteoNic’s premium expression vector technology 2G UNic.

Find out how our enhanced CLD solution provides the foundation of biopharmaceutical development success and mitigates risk. For molecules such as mAbs, Fabs and Fc fusions, we streamline timelines using our AbZelectPRO™ platform methodology. For novel and complex molecules, our AbZelectPRO™ platform also allows us to design and develop a rapid, robust approach to your program.

Download Info Sheet Discover AbZelectPRO™

What sets our cell line development services and solutions apart?

  • We offer an integrated cell line development process, shortening timelines to IND enabling material, supported by using fast stable pools to generate early-stage material for characterization, pre-formulation, analytics and lead molecule selection.
  • For complex biologic programs, we deliver increased productivity through our AbZelectPRO™ platform, which combines our existing CHO cell line with ProteoNic’s premium expression vector technology 2G UNic.
  • We maintain biosimilarity, critical for the regulatory, by developing your biosimilar cell line using the originator cell type.
  • Applying our technologies and experience in proteomics, protein engineering, bioconjugation and formulation development, we design novel subunit and conjugate vaccine candidates.
  • We have the flexibility and expertise to apply our processes to other proprietary host cell lines including; SP2-0, NS0, PER.C6, CHO-ZN, CHO BIOP3.
  • Streamline your biologics development program with our GMP-compliant cell line characterization approach.
Contact Us

Enhanced AbZelectPRO™ platform with 2G UNic by ProteoNic

AbZelectPRO™ delivers increased productivity by combining our existing CHO cell line with ProteoNic’s premium expression vector technology 2G UNic.

Benefits of AbZelectPRO™ with 2G UNic vector technology

  • Optimized expression cassettes to maximize productivity from each cell
  • Efficient GS selection marker compatible with current AbZelectPRO™ CHO Cell Line
  • Proven track record – ProteoNic are moving towards regulatory approvals with multiple programs in the clinic and work with several large pharmaceutical firms.
  • Early material from highly productive stable pools for antibodies, bispecifics and fusion proteins
  • Higher frequency of high-producing clones offering more shots on goal- up to 8 g/L
  • Highly stable clones maintaining productivity beyond 60 generations
  • Quicker doubling times with a >30% reduction in cell line development timelines
  • Uses single-use bioreactors to lower production costs
  • Robust scalable and consistent platform process
  • Further process intensification can boost titres to achieve 10g/L at scale
  • Enhanced cycle times with faster growth with optimized CHO-K1 host cell line

How AbZelectPRO™ with 2G UNic vector technology works

ProteoNic’s 2G UNic technology uses the combined effect of novel genetic elements to exert a positive effect on recombinant protein production levels and boosts the performance of other expression-enhancing technologies.  This state-of-the art vector technology also increases production levels of difficult-to-produce complex protein, including bispecifics and fusion proteins as well as levels of products already in the multiple g/L range.

Technical Evaluation of our Enhanced AbZelectPRO™ Platform

  • 3x higher stable pool productivity for antibodies and fusion proteins
  • Higher frequency of high-producing clones offering more shots on goal
  • High number of high-producing clones >8 g/L
  • 100% of selected clones stable after 60 generations

Connect with us today to learn how our newly enhanced AbZelectPRO platform, using 2G UNic can help improve the chances of success for your complex biologic program.

Contact Us

Discover AbZelectPRO™

About AbZelectPRO™

Move your cell line development efficiency forwards with our AbZelectPRO™ platform.

Learn More

AbZelectPRO™ Info Sheet

AbZelectPRO™ reduces the lead candidate sequence to RCB timeline.

Learn More

AbZelectPRO™ News

AbZelectPRO™ enables biopharma customers to reach their research cell bank in 10 weeks with 8g/L.

Learn More

Related Services

Biosimilar Cell Line Development

We help you maintain biosimilarity, critical for the regulatory approval of biosimilar products, by developing your cell line using the originator cell type.

Learn More

Cell Line Characterization

The safety and quality of your biologic product starts with the right cell line, discover our GMP-compliant cell line characterization methods.

Learn More

Research Cell Banking (RCB)

From transfection pools or non-clonal cell lines we apply our robust single cell cloning process to rapidly isolate and identify the most productive monoclonal populations.

Learn More

Vaccine Development

Applying our solutions and experience in proteomics, protein engineering, bioconjugation and formulation development, we design novel subunit and conjugate vaccine candidates.

Learn More

Analytical Development

Your product development program will be accelerated by leveraging our expansive in-house capabilities, technologies, and knowledge to deliver methods tailored to your molecule of interest.

Learn More

Process Development

We use our knowledge of cGMP manufacturing to transfer or develop the most effective processes for manufacturing at toxicology, clinical, and commercial scale.

Learn More